Market Cap (In USD)
11.65 Million
Revenue (In USD)
-
Net Income (In USD)
-10 Million
Avg. Volume
15.49 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.9-4.4
- PE
- -
- EPS
- -
- Beta Value
- 0.951
- ISIN
- US00972G2075
- CUSIP
- 00972G108
- CIK
- 1541157
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Samir Rashmikant Patel M.D.
- Employee Count
- -
- Website
- https://www.akaritx.com
- Ipo Date
- 2014-01-06
- Details
- Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
More Stocks
-
BBTC
-
TCPI
-
BCGWW
-
2972
-
DMND
-
TPIA
-
9342Sumasapo Inc.
9342
-
RTNPOWERRattanIndia Power Limited
RTNPOWER